THE ROLE OF CALCIUM CHANNEL BLOCKERS IN THE TREATMENT OF ARTERIAL HYPERTENSION AND THE MECHANISM OF ACTION
Keywords:
Keywords: Chronic kidney disease, glomerulosclerosis, calcium channel blockers, remodeling, dihydropyridine, lercanidipine.Abstract
At the end of the 20th and the beginning of the 21st century, the global
community faced a worldwide issue that is not only medical but also has significant
socio-economic implications — the pandemic of chronic diseases. Chronic conditions
such as diabetes, heart, lung, and kidney diseases, as well as their various combinations,
are now observed in nearly every individual. High-tech intensive and replacement
therapies can save lives, but they do not always ensure the preservation of life quality,
work capacity, and social activity. Moreover, simple and affordable preventive
measures are often underutilized, diseases are diagnosed late, and patients frequently
lack motivation and commitment to a healthy lifestyle.
Early clinical and laboratory signs of kidney damage are often vague and go
unnoticed by physicians, particularly in elderly patients. These initial symptoms are
often perceived as part of the "age norm."
Among chronic non-communicable diseases, chronic kidney disease (CKD)
occupies a special place due to its high prevalence, significant reduction in quality of
life, and high mortality rates. At its terminal stage, CKD necessitates expensive
treatments such as dialysis or kidney transplantation. However, none of the existing
kidney replacement therapies are flawless: they fail to fully restore kidney function and
carry the risk of complications.
References
References:
1. А.М.Шилов.Первый московский государственный медицинский
университет им. И.М.Сеченова.» Местоблокаторов кальциевых каналов
третьего поколения в континууме метаболического синдрома.
Антигипертензивная терапия.Трудный пациент №4 ТОМ,12, 2014.20-21стр.
2. А.М. Шутов Хроническая болезнь почек — глобальная проблема XXI века,
2014 удк 616.61-036.12. Клиническая медицина, № 5, 2014 7стр.
3. Бубнова М.Г. Антагонисты кальция и нефропротекция: современное
положение и перспекти-вы препарата нового поколения лерканидипина/
М.Г. Бубнова // CardioСоматика. ― 2011. ― № 3. – С. 46-50.
4. О.Н.Сигитова.»Современные клинические рекомендации по лечению
артериальной гипертензии у пациентов с хронической болезнью почек».г.
Казань.Консилиум.№ 1 (151) январь – февраль, 2017.23стр.
5. Сиренко, Ю.Н. Дигидропиридиновые антагонисты кальция – новый резерв
снижения риска осложнений при артериальной гипертензии/ Ю.Н. Сиренко
// Артериальная гипертензия. ― 2010. ― № 9.
http://medstrana.com/articles/4010//
6. Сливка Н.А. Патоморфологические изменения почек при гепаторенальном
синдроме XLII Международной научно-практической конференции
“Экспериментальные и теоретические исследования в современной науке”
Россия,г.Новосибирск, 26июня 2019г.
7. Шилов Е.М., Смирнов А.В., Козловская Н.Л. – М.: ГЭОТАР-Медиа
Нефрология. Клинические рекомендации. 2016, 816 стр.
8. Blvarez C., Gуmez E., Simуn M. atal. Differences in Lercanidipinesys temic
exposure when administered according to labeling: in fasting state and 15 minutes
before food intake. Eur. J. Clin. Pharmacol. 2012;68: 1043–1047
9. Cepoi V., Onofriescu M., Segall L., Covic A. The prevalence ofchronic kidney
disease in the general population in Romania: a studyon 60,000 persons. Int. Urol.
Nephrol. 2012; 44: 213—20.
10. Chalmers J., Arima H., Harrap S. et al. Global survey of current practice in
management of hypertension as reported by societies affiliated with the
international society ofhypertension. J Hypertens, 2013; Feb 2710. Collins A.J.,
Foley R.N., Herzog C. et al. United States renal data system 2008. Annual data
report. Am. J. KidneyDis. 2009; 53: S1—374.
11. Crews D.C., Plantinga L.C., Miller E.R. etal. Prevalence of chronic kidney disease
in persons with undiagnosed or prehypertension in the United States. Hypertension.
2010; 55: 1102—9.
12. Duru O.K., Vargas R.B., Kermah D. et al. High prevalence of stage 3 chronic
kidney disease in older adults despite normal serum creatinine. J. Gen. Intern. Med.
2009; 24: 86—92.
13. Eggers P.W. Has the incidence of end-stage renal disease in the USAand other
countries stabilized? Curr. Opin. Nephrol. Hypertens.2011; 20: 241—5.
14. Farah R.,Khamisy-Farah R., Shurtz-SwirskiR. Calcium channel blocker effect on
insulin resistance and inflammatory markers in essential hypertension patients. Int
Angiol, 2013;32:85–93
15. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of
Chronic Kidney Disease. KidneyInt. Suppl. 2013; 3:1—150.
16. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic
Kidney Disease: Evaluation, Classification andStratification. Am. J. KidneyDis.
2002; 39 (Suppl 1):S1—266.
17. Rump L. C. Efficacy and tolerability of the fixed lercanidipine-enalapril
combination in thetreatment of patients with essential hypertension. Arzneimittel
for schung, 2010; 60:24–30.
18. Zhang J., Cao H., Zhang Y. et al. Nephroprotective effect of calcium channel
blockers against toxicity of lead exposure in mice. Toxicol Lett, 2013; Feb 18.
